RxSight Inc. (RXST), an ophthalmic medical device company, which reported an impressive 57% year-over-year revenue growth in 2024, is projecting continued success in 2025.
The company markets its proprietary, FDA-approved RxSight Light Adjustable Lens (LAL) system, which is designed to enhance the outcomes of post-cataract surgery patients. The LAL system includes the Light Adjustable Lens (LAL), the Light Delivery Device (LDD), and a range of essential accessories.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com